Literature DB >> 10404792

[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.

W Wang1, H Macapinlac, S M Larson, S D Yeh, T Akhurst, R D Finn, J Rosai, R J Robbins.   

Abstract

Progressive dedifferentiation of thyroid cancer cells leads to a loss of iodine-concentrating ability, with resultant false negative, whole body radioactive iodine scans in approximately 20% of all differentiated metastatic thyroid cancer lesions. We tested the hypothesis that all metastatic thyroid cancer lesions that did not concentrate iodine, but did produce thyroglobulin (Tg), could be localized by [18F]2-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET). We performed FDG-PET on 37 patients with differentiated thyroid cancer after surgery and radioiodine ablation who had negative diagnostic 131I whole body scans during routine follow-up. Serum Tg, Tg autoantibodies, neck ultrasounds, and other clinically indicated imaging procedures were performed to detect residual disease. In those with elevated Tg levels, FDG-PET localized occult disease in 71%, was false positive in one, and was false negative in five patients. The majority of false negative FDG-PET occurred in patients with minimal cervical adenopathy. Surgical resections, biopsies, 131 therapy, and differentiation therapy were performed based on the PET results. The FDG-PET result changed the clinical management in 19 of the 37 patients. In patients with elevated Tg levels, FDG-PET had a positive predictive value of 92%. In patients with low Tg levels, FDG-PET had a negative predictive value of 93%. No FDG-PET scans were positive in stage I patients; however, they were always positive in stage IV patients with elevated Tg levels. An elevated TSH level (i.e. hypothyroidism) did not increase the ability to detect lesions. FDG-PET is able to localize residual thyroid cancer lesions in patients who have negative diagnostic 131I whole body scans and elevated Tg levels, although it was not sensitive enough to detect minimal residual disease in cervical nodes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404792     DOI: 10.1210/jcem.84.7.5827

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  47 in total

Review 1.  The management of metastatic differentiated thyroid carcinoma.

Authors:  S I Sherman
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

3.  2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer.

Authors:  Andrei Iagaru; Rinat Masamed; Peter A Singer; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

4.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

5.  Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody.

Authors:  Su Jung Choi; Kyung Pyo Jung; Sun Seong Lee; Yun Soo Park; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2015-10-22

6.  Transoral Surgical Approach for Retropharyngeal Node Involvement in I-131-Negative 18-fluoro-2-deoxyglucose Positron Emission Tomography-Positive Recurrent Thyroid Cancer.

Authors:  Quang D Ma; Kate Grimm; Benjamin I Paz; Ellie Maghami
Journal:  Skull Base       Date:  2009-11

7.  The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma.

Authors:  Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Brian P Mullan; Ian D Hay
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

8.  Challenging cases in thyroid cancer: a multidisciplinary approach.

Authors:  Michael Tuttle; Richard Robbins; Steven M Larson; H William Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

Review 9.  Role and cost effectiveness of PET/CT in management of patients with cancer.

Authors:  Muhammad Wasif Saif; Ifigenia Tzannou; Nektaria Makrilia; Kostas Syrigos
Journal:  Yale J Biol Med       Date:  2010-06

10.  Influence of TSH on uptake of [18F]fluorodeoxyglucose in human thyroid cells in vitro.

Authors:  J T Deichen; C Schmidt; O Prante; S Maschauer; T Papadopoulos; T Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.